• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oruka Therapeutics (ORKA) As Positive Psoriasis Trial Data Tests A Pricey Valuation

    Simply Wall St·11/03/2026 15:24:53
    语音播报

    Oruka Therapeutics (ORKA) drew fresh attention on 26 October 2026 after reporting positive Week 16 Phase 2b EVERLAST-B data for ORKA-001 in moderate to severe psoriasis, with the high-dose arm meeting key efficacy and safety goals.

    Despite the positive EVERLAST-B update, Oruka Therapeutics’ 1-day share price return declined 1.5% to close at US$95.43 on 1 November. However, a 30-day share price return of 12.9% and a very large year-to-date share price gain of 237.6% point to strong momentum. The 1-year total shareholder return of 247.9% highlights how clinical progress and shifting risk expectations have already been reflected in the valuation.

    Scan beyond Oruka Therapeutics and see how other clinically driven biopharma stocks are setting up in the 19 high quality undiscovered gems right now.

    For Oruka Therapeutics, a small pullback after a very large year to date surge raises a simple puzzle. Are you mainly seeing stronger fundamentals being repriced, or sentiment stretching the multiple beyond those trial headlines?

    Preferred Price-to-Book of 5.7x: Is It Justified for Oruka Therapeutics?

    On the latest figures, Oruka Therapeutics trades on a Price-to-Book ratio of 5.7x, which sits well above the wider US Biotechs industry average of 1.8x. With the share price last closing at $95.43 and a 1-year total shareholder return of 247.9%, the question many investors are now asking is whether that 5.7x multiple reflects fundamental progress or enthusiasm running ahead of the balance sheet.

    The P/B multiple compares a company’s market value to its net assets. For early stage biopharma groups like Oruka Therapeutics that report no revenue and a net loss of $109.688m, investors often focus on this ratio because earnings based metrics are not yet meaningful. A higher P/B in this context usually signals that the market is placing a sizeable value on the drug pipeline, intellectual property, and management’s ability to turn clinical data into future cash flows.

    Here the numbers pull in different directions and you need to weigh them. ORKA is described as unprofitable, forecast to remain loss making over the next 3 years, and expected to see earnings decline by an average of 24.2% per year in that period. At the same time, the stock has delivered a very large gain over the past year and analysts have set a price target of $156.17, which sits 38.9% above the last close, although those forecasts are not within a statistically confident range of agreement. That mix suggests a market that is willing to pay a rich P/B multiple for clinical potential while accepting a long and uncertain road to profitability.

    Against peers, the contrast is sharp. Oruka Therapeutics trades on a 5.7x P/B, which is described as expensive compared with the broader US Biotechs industry average of 1.8x. Yet the same 5.7x is labelled good value when lined up against a much higher 43.3x peer average, which hints at a pocket of the sector where valuations run far hotter. For anyone looking at ORKA, the decision comes down to whether the current phase 2 programs and early pipeline justify paying well above the wider industry, but below the most aggressively valued peer group.

    Result: Preferred Price-to-Book of 5.7x (OVERVALUED)

    See what the numbers say about this price — find out in our valuation breakdown.

    Still, the story around Oruka Therapeutics can shift quickly if Phase 2 data disappoint, or if further losses of $109.688m deepen without clear funding visibility.

    Find out about the key risks to this Oruka Therapeutics narrative.

    Next Steps

    Feeling cautious after all this enthusiasm around Oruka Therapeutics, especially with recent losses and a rich P/B multiple, is reasonable. Act quickly and stress test your own thesis by reviewing the 5 important warning signs.

    Looking for more Oruka Therapeutics sized opportunities?

    If Oruka Therapeutics has sharpened your focus on risk and reward, do not stop here. Your next strong idea might already be waiting in the Simply Wall St screener.